Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Extendin-4
Drug ID BADD_D00863
Description Exenatide is a glucagon-like peptide-1 (GLP-1) analog[Label]. It functions to activate the GLP-1 receptor and increases insulin secretion, decrease glucagon secretion, and slow gastric emptying to improve glycemic control[Label]. Exenatide was given FDA approval on April 28, 2005[L6106].
Indications and Usage Exenatide is indicated for improving glycemic control in adults with type 2 diabetes mellitus along with diet and exercise[Label].
Marketing Status approved; investigational
ATC Code A10BJ01
DrugBank ID DB01276
KEGG ID D04121
MeSH ID D000077270
PubChem ID 16157882
TTD Drug ID D00YVF
NDC Product Code 52416-125; 0310-6540; 41524-0003; 69766-078; 68067-0397; 0310-6512; 0310-6524; 52416-105; 0406-7310; 59149-004
UNII 9P1872D4OL
Synonyms Exenatide | Bydureon | ITCA 650 | AC 2993 LAR | Exendin-4 | Ex4 Peptide | Peptide, Ex4 | Exendin 4 | Byetta | AC 2993
Chemical Information
Molecular Formula C184H282N50O60S
CAS Registry Number 141758-74-9
SMILES CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN )C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC( C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC( =O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C( CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO )NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC (=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CN=CN9)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Feeling jittery08.01.09.016--Not Available
Flatulence07.01.04.002--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.002--
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site dermatitis12.07.03.041; 08.02.03.041; 23.03.04.033--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haematoma24.07.01.009; 12.07.03.004; 08.02.03.004--Not Available
Injection site induration12.07.03.007; 08.02.03.007--Not Available
Injection site mass08.02.03.009; 12.07.03.010--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site pruritus12.07.03.014; 08.02.03.013; 23.03.12.007--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
International normalised ratio increased13.01.02.008--
Loss of consciousness17.02.04.004--Not Available
Muscle spasms15.05.03.004--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages